Learn About Primary Immunodeficiency (PID)
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Veros Health
Isaac Melamed is a Pediatrics provider in Longmont, Colorado. Dr. Melamed is rated as an Elite provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Primary Immunodeficiency (PID), Common Variable Immune Deficiency, Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus Infections, and Hereditary Angioedema.
Montefiore Medical Center
Arye Rubinstein is an Allergy and Immunologist in Bronx, New York. Dr. Rubinstein is rated as an Elite provider by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Primary Immunodeficiency (PID), Common Variable Immune Deficiency, Adenosine Deaminase Deficiency, and Immunodeficiency with Hyper IgM Type 1.
Andrew Gennery practices in Newcastle Upon Tyne, United Kingdom. Mr. Gennery is rated as an Elite expert by MediFind in the treatment of Primary Immunodeficiency (PID). His top areas of expertise are Primary Immunodeficiency (PID), Severe Combined Immunodeficiency (SCID), Chronic Granulomatous Disease, Bone Marrow Transplant, and Heart Transplant.
Summary: The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). ...
Summary: This is an open-label, multicenter, phase 4 study in IG treatment-naïve participants with PID, conducted in the United States (US), to assess the PK, safety, and tolerability of IgPro20. The primary objective of this study is to characterize the PK of IgPro20 and to assess the safety and tolerability of IgPro20 in IG treatment-naïve participants with PID who are aged greater than or equal to (\>=)...